New Treatment Options for Depression: A Primer for Internists.

Am J Med

Division of Community Internal Medicine, Mayo Clinic, Scottsdale, Ariz.

Published: June 2019

Depression continues to be a challenging condition to treat despite the myriad treatment options available. Primary care providers are increasingly tasked with providing second- and third-line treatments for major depressive disorder, and thus, should be familiar with newer medication therapies that are available. In this article, we aim to provide the general internist and other providers who treat depression in their practice with a succinct review of recent developments in the treatment of depression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2019.01.012DOI Listing

Publication Analysis

Top Keywords

treatment options
8
depression
4
options depression
4
depression primer
4
primer internists
4
internists depression
4
depression continues
4
continues challenging
4
challenging condition
4
condition treat
4

Similar Publications

Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes.

Int J Retina Vitreous

January 2025

Fondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Avenue de France 54, Lausanne, 1001, Switzerland.

Background: This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month.

Methods: A retrospective, single-center cohort study was conducted at the Jules Gonin Eye Hospital, Lausanne, Switzerland. Clinical records of treatment-naïve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed.

View Article and Find Full Text PDF

Purpose: The prognosis of relapsed primary central nervous system lymphoma remains a concern. This study aimed to compare the effects of various patient- and disease-related factors on the prognosis of relapsed primary central nervous system lymphoma (PCNSL).

Methods: We retrospectively collected real-world data from eight Finnish hospitals on 198 patients diagnosed with PCNSL between 2003 and 2020.

View Article and Find Full Text PDF

Human adenovirus is an infectious agent that causes respiratory infections in adults and children. It has been found that immunocompromised children are highly susceptible to this pathogen, as it can swiftly evolve into severe pneumonia with multiple sequelae. Due to the lack of immunity in children, the body's response mechanisms to innate and acquired immunity are specialized.

View Article and Find Full Text PDF

Background: Delayed prescription is a strategy used in various countries to reduce antibiotic overuse and contend the effects of antibiotic resistance; however this practice is not yet used in Switzerland. The present qualitative study was thus conducted to investigate Swiss patients' attitudes towards the possible implementation of delayed prescription.

Method: Five focus groups with the general population based on a fixed script of questions to elicit opinions on delayed prescription.

View Article and Find Full Text PDF

Preterm infants are at high risk of developing respiratory distress syndrome (RDS). Mutations in the genes encoding for surfactant proteins B and C or the ATP-binding cassette transporter A3 (ABCA3) are rare but known to be associated with severe RDS and interstitial lung diseases. The exact prevalence of these mutations in the general population is difficult to determine, as they are usually studied in connection with clinical symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!